ExodusPoint Capital Management’s Sutro Biopharma STRO Stock Holding History

ExodusPoint Capital Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,801	Closed	-$714K	–	2656
2021 Q4	$714K	Buy	4,801 +2,275	+90%	+$408K	0.01%	1241
2021 Q3	$477K	Buy	+2,526	New	+$480K	0.01%	1426
2021 Q2	–	Sell	-4,647	Closed	-$1.06M	–	2784
2021 Q1	$1.06M	Buy	4,647 +1,012	+28%	+$240K	0.02%	882
2020 Q4	$789K	Buy	+3,635	New	+$602K	0.01%	986

Other funds holding STRO

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

ExodusPoint Capital Management's STRO Position: Q1 2022 in Review

ExodusPoint Capital Management sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 4,801 shares — an estimated $714K sold.

ExodusPoint Capital Management first reported a position in STRO in Q4 2020 and held it in 4 quarters. The position peaked at $1.06M in Q1 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

ExodusPoint Capital Management reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 4,801 Sutro Biopharma shares in Q1 2022, an estimated $714K.
ExodusPoint Capital Management first reported a position in Sutro Biopharma in Q4 2020 and held it in 4 quarters.
ExodusPoint Capital Management's Sutro Biopharma position peaked at $1.06M in Q1 2021.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.